Generate Biomedicines director buys shares, gets options

Generate Biomedicines director Jane L. Mendillo reported two transactions involving the company’s securities.

Rhea-AI Filing Summary

Generate Biomedicines director Jane L. Mendillo reported two transactions involving the company’s securities. On March 2, 2026, she made an open-market purchase of 1,500 shares of Common Stock at $16.00 per share, bringing her directly held common shares to 1,500.

On February 26, 2026, she also received a grant of 29,561 stock options with an exercise price of $0.00. According to the disclosure, the shares underlying this option vest in full on February 19, 2027, subject to her continued service with the company on that vesting date.

Insider Trade Summary

Net Buyer: 1,500 shares

Net Buy 2 txns

Insider Mendillo Jane L

Role Director

Bought 1,500 shs ($24K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,500	$16.00	$24K
Grant/Award	Stock Option (Right to Buy)	29,561	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 29,561 contracts (Direct); Common Stock — 1,500 shares (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Jane L. Mendillo report for Generate Biomedicines (GENB)?

Jane L. Mendillo reported buying 1,500 shares of Generate Biomedicines common stock and receiving 29,561 stock options. The stock purchase was an open-market transaction, while the options were granted as an award that vests in full on February 19, 2027.

How many Generate Biomedicines (GENB) shares did the director buy and at what price?

She bought 1,500 shares of Generate Biomedicines common stock at $16.00 per share. This open-market purchase increased her directly held common stock position to 1,500 shares immediately following the transaction, according to the reported Form 4 data.

What are the terms of the 29,561 Generate Biomedicines (GENB) stock options granted to Jane L. Mendillo?

She received 29,561 stock options with a reported exercise price of $0.00 per share. All shares underlying this option grant will vest in full on February 19, 2027, provided she continues to serve the company through that vesting date.

When do Jane L. Mendillo’s Generate Biomedicines (GENB) stock options vest?

The stock options vest in full on February 19, 2027. Vesting is conditioned on her continued service to Generate Biomedicines through that date, meaning she must still be serving the company for the entire option grant to become exercisable.

Are Jane L. Mendillo’s Generate Biomedicines (GENB) holdings direct or indirect?

The reported holdings are classified as direct ownership. Both the 1,500 shares of common stock purchased and the 29,561 stock options granted are listed with a direct ownership code, and no related entities or indirect ownership structures are disclosed.

Did the Form 4 for Generate Biomedicines (GENB) include any stock sales by Jane L. Mendillo?

No stock sales were reported in this Form 4. The filing shows one open-market purchase of 1,500 common shares and one acquisition of 29,561 stock options via a grant, with no dispositions or sales of Generate Biomedicines securities disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 05:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mendillo Jane L

(Last) (First) (Middle)

GENERATE BIOMEDICINES, INC.

101 SOUTH STREET, SUITE 900

(Street)

SOMERVILLE MA 02143

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Generate Biomedicines, Inc. [ GENB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		P		1,500	A	$16	1,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16	02/26/2026		A		29,561		(1)	02/25/2036	Common Stock	29,561	$0	29,561	D

Explanation of Responses:

1. The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

	/s/ Michael Wolf, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.